Rafarma Pharmaceuticals, Inc. Receives General License for
Pharmaceutical Products and has Started to Manufacture 3 New
Products
SANDY, Utah, Feb. 4, 2013 /PRNewswire/ -- Rafarma
Pharmaceuticals, Inc. (the "Company") OTC symbol (RAFA) announced
that it has received the general license for pharmaceutical
products and has started the manufacturing of 3 new products.
The general license was one of the final steps required to open the
new plant in Terbuniy. The Company is now in operation and is
expected to rapidly increase to 100% capacity of the Terbiniy
facility with the addition of government contracts provided by
being 1 of 4 National Strategic Pharmaceutical Suppliers to the
Russian Federation.
The new products are Sodium Para-Aminosalicilate, Ibuprofen, and
Betagistin. Sodium Para-Aminosalicilate is a tablet with a
time release cover. The current dosage manufactured is 1000 mg and
is designed to be of use against various forms of tuberculosis.
Sodium Para-Aminosalicilate can also be used in conjunction with
other anti-tuberculosis medications. The Ibuprofen
manufactured is Rectal Suppositories for children and the currently
manufactured dosage is 60 mg. Betagistin Tablets are
manufactured in dosages of 8 mg, 16 mg and 24 mg. The product is
used to treat Manier Syndrome which is characterized by drowsiness,
nausea, reduction in hearing abilities and noise in the ears. It is
also used as treatment of vestibular vertigo.
Julia Andrushkova, a company spokesperson, was quoted as
saying: "Receiving the general license for pharmaceutical
products has been a major step to success for the many people
involved, and for the Company in general."
Safe Harbor Statement
Matters discussed in this press release contain forward-looking
statements within the meaning of the Private Securities Litigation
Reform Act of 1995. When used in this press release, the words
"anticipate," "believe," "estimate," "may," "intend,"
"expect" and similar expressions identify such forward-looking
statements. Actual results, performance or achievements could
differ materially from those contemplated, expressed or implied by
the forward-looking statements contained herein. These
forward-looking statements are based largely on the expectations of
the Company and are subject to a number of risks and uncertainties.
These include, but are not limited to: the impact of economic,
competitive and other factors affecting the Company and its
operations, markets, product, and distributor performance.
SOURCE Rafarma Pharmaceuticals, Inc.